Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rapid Dose Therapeutics's Debt-to-Equity or its related term are showing as below:
RDTCF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -8.26 Med: -0.7 Max: 4.66
Current: -0.68
During the past 13 years, the highest Debt-to-Equity Ratio of Rapid Dose Therapeutics was 4.66. The lowest was -8.26. And the median was -0.70.
RDTCF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs RDTCF: -0.68
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rapid Dose Therapeutics Debt-to-Equity Related Terms
Rapid Dose Therapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RDTCF vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Rapid Dose Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Dose Therapeutics (RDTCF) has a Debt-to-Equity of -0.68 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rapid Dose Therapeutics and its competitors. According to the industry distribution chart, Rapid Dose Therapeutics ranks #999999 out of 962 companies in the Biotechnology industry.
Is Rapid Dose Therapeutics' Debt-to-Equity too high?
Rapid Dose Therapeutics' current Debt-to-Equity is -0.68. Based on the distribution chart, Rapid Dose Therapeutics ranks #999999 out of 962 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rapid Dose Therapeutics has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #999999 out of 962 companies for Debt-to-Equity. This places Rapid Dose Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rapid Dose Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Dose Therapeutics's current Debt-to-Equity is -0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.20, compared to a current price of $0.09 — trading 57.5% below its estimated fair value. The current Debt-to-Equity is -0.68. Rapid Dose Therapeutics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Debt-to-Equity is -0.68 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued.
The current stock price of $0.09 is trading 57.5% below its estimated GF Value™ of $0.20.
GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.
Key valuation signals for RDTCF:
Debt-to-Equity: -0.68
GF Value™: $0.20 vs. price of $0.09 (57.5% below fair value)
No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
24GF Score
Get the complete analysis for RDTCF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
